Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SJX‑653

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SJX‑653

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 08, 2020

            Details:

            Sojournix has resumed its Phase 2 trial of SJX-653, a novel, potent, and selective neurokinin 3 (NK3) antagonist in development as a non-hormonal once-daily treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SJX-653

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SJX-653

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2020

            Details:

            Poster presentation of data showing SJX-653 exhibits a potent NK3 antagonist profile across in vitro studies, in vivo models, and initial clinical studies in men and postmenopausal women, will be presented at the 2020 North American Menopause Society Virtual Annual Meeting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SJX-653

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SJX-653

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 21, 2020

            Details:

            SJX-653 demonstrated statistically significant and dose-dependent effects on pharmacodynamic markers of NK3 antagonism. SJX-653 exhibited a plasma half-life supporting once-daily (QD) dosing and was well tolerated.